Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2006

View Archived Issues

Nalmefene shows promise in treating pathological gambling / News in Context

NXY-059 appears to reduce disability in ischemic stroke patients

LRH-1 activation: Potential efficacy as a treatment for atherosclerosis

New localized radiotherapeutic for prostate cancer

Capsaicin patch reduces pain in HIV-associated distal sensory polyneuropathy

GCPII inhibitor targeted for neuroprotection and prostate cancer

Neurochem completes rolling NDA for Fibrillex in AA amyloidosis

Phase I study of lemuteporfin in BPH fails to meet primary efficacy objective

Santen updates status of ophthalmic programs

ProMetic BioSciences cleared for Canadian phase Ib/II study of PBI-1402

Ranbaxy and CIH establish joint venture for antiretrovirals in South Africa

Eltrombopag begins phase III trials for ITP

Avant's typhoid fever vaccine Ty-800 studied in new phase I/II trial

BioXell and Lay Line Genomics sign agreement for MNAC13

European COMP recommends orphan drug designation for 1D09C3

Orthokine approved in E.U.

Glenmark discovers new drug targeting obesity

Retapamulin NDA under FDA review

Pfizer looks to value drivers to grow business

Prophylactic and therapeutic efficacy of targeting TLR9 for HSV-2

Recent Incyte patent describes new therapeutic agents for HIV infection

New agents for endocrine-related disorders imparted in recent patent literature

Orphan drug designation for TRX-4 in type 1 diabetes

Phase Ib trial investigates AP-23573 plus doxorubicin for cancer

MB-07803 studied in phase I for type 2 diabetes

New therapeutic agents described for cardiovascular disorders

Japanese phase II trial for gaboxadol

Ambrisentan use in PAH patients who discontinue other ERA therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...